尊龙时凯

2016/12/09

CHINA FOOD AND DRUG ADMINISTRATION APPROVES SIRTURO® (BEDAQUILINE) FOR PATIENTS WITH PULMONARY MULTI-DRUG RESISTANT TUBERCULOSIS (MDR-TB)

[1 December 2016, Beijing] – Xian Janssen Pharmaceutical Ltd. today announced that the China Food and Drug Administration (CFDA) has approved SIRTURO® (bedaquiline) for use as part of c...

2016/10/30

2nd Holistic Integrative Medicine Forum held by Xian Janssen and Shanghai Johnson and Johnson in Beijing

October 30, 2016, Beijing——The 2nd Holistic Integrative Medicine Forum, organized by Xian Janssen Pharmaceutical Ltd.

2016/08/18

XIAN JANSSEN LAUNCHES THE FIRST “8.27 ANKYLOSING SPONDYLITIS DISEASE AWARENESS DAY”

[Xi’an, August 17, 2016] Xian Janssen is launching China’s first Ankylosing Spondylitis (AS) Awareness Day on 27 August 2016 to encourage those at ‘high risk’ of AS, an extremely debilitating conditio...

2016/08/12

Statement

Xian Janssen is aware of recent media reports regarding domperidone-containing medicines, including MOTILIUM®. As with all of our medicines, patient safety is of paramount importance to Xian Janssen.

2016/07/28

World Hepatitis Day 2016: KNOW HEPATITIS, ACT NOW!

2016/07/14

VELCADE® Added to the Reimbursement List for Drugs Treating Major Illnesses in Hunan Province

-- Patients with multiple myeloma and mantle cell lymphoma now eligible for drug reimbursement

2016/04/27

Ankylosing spondylitis and rheumatoid arthritis included as outpatient special diseases covered by urban basic medical insurance in Xi'an

—— Outpatient use of Remicade® (infliximab injection) eligible for reimbursement

2016/02/25

Johnson & Johnson Issues Call for Innovative Ideas to Reduce HIV Infections in Sub-Saharan Africa

DREAMS Partners Announce $85 Million Innovation Challenge Focused on Solutions for Adolescent Girls and Young Women

2016/01/14

CHINA FOOD AND DRUG ADMINISTRATION APPROVES COMPLERA® FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS-1(HIV-1) INFECTION

[Beijing],[14 January 2016] – Xian Janssen Pharmaceutical Ltd. announced today that the China Food and Drug Administration has granted regulatory approval for COMPLERA® as a complete single-tablet reg...

2015/11/03

Remicade®, Velcade® and Invega Sustenna® enter the list of drugs under the coverage of supplementary medical insurance for major and critical diseases in Shenzhen

(November 3, 2015, Shenzhen) The Human Resources and Social Security Administration of Shenzhen Municipality recently announced the implementation of Shenzhen’s supplementary medical insurance for maj...